

Status review: implementation of the HTA Regulation

EAA Convention 6 November 2025

Valentina Barbuto
Policy Officer, Unit C2 – Health Technology Assessment
Directorate-General for Health and Food Safety, European Commission

Key actions for the Commission

- Secretariat function for the HTA Coordination Group and its four subgroups
- ❖ Adoption of implementing acts and other **legal** support
- Supervision of the procedures, incl. requests to the health technology developer
- Decisions on conflict of interest for national representatives and experts
- Identification of individual experts
- ❖ Management of the IT Platform and HTA Europa page
- Facilitation of the cooperation with the European Medicines Agency






Implementing Regulations on HTA

1 st	Procedural rules for <u>JCA of medicinal products</u>	2024/1381	Adopted 23 May 2024
2 nd	Procedural rules on the <u>cooperation with the EMA</u>	2024/2699	Adopted 18 October 2024
3rd	Procedural rules for the management of conflicts of interest	2024/2745	Adopted 25 October 2024
4 th	Procedural rules for <u>JSC of medicinal products</u>	2024/3169	Adopted 18 December 2024
5 th	Procedural rules for JSC of medical devices and IVD medical devices	2025/117	Adopted 24 January 2025
6 th	Procedural rules for JCA of medical devices and IVD medical devices	2025/2086	Adopted 17 October 2025



Joint Clinical Assessments (10 ongoing)



13 EU/EEA
Countries
currently involved
in at least one
JCA



Joint Scientific Consultations

- 2025: 2 requests periods (3 February to 3 March and 2 to 30 June)
- 7 products selected and companies informed
 - 4 parallel consultations with EMA
 - 2 Joint Scientific Consultations



 Request periods for 2026 will be published in the HTA Coordination Group 2026 Work programme and on the Europa website



Identification and selection of patients and clinicians in joint work

HTA Stakeholder
Network Working
Group to co-create the
process

Information on the expertise needed from Joint Clinical Assessment or Joint Scientific Consultation Subgroup Outreach to the HTA Stakeholder Network; Coordination Group and other sources for profiles Invite patients and clinicians to fill out a Declaration of Interest and submit a CV Check of **Declarations of Interests** Propose to Joint Clinical Assessment or Joint Scientific **Consultation Subgroup Joint Clinical Assessment or Joint Scientific Consultation Subgroup** selects patients and clinicians

Contracts by the Brussels Centre for Collaboration in Health



Identifications of experts - State of play

17 patients/carers provided input to assessment scope

> 200 patients/carers and clinicians invited to fill in a Declaration of Interest > 40 patients/carers and clinicians selected for Joint Clinical Assessments and Joint Scientific Consultations

New dedicated IT helpdesk for patients and clinicians

Additional communication material and guidance on conflict of interest

Upcoming new Europa website page on involvement of patients and clinicians



IT Platform – State of play

- 9 JCA workflows open.
- 6 JSC workflows open.
- 77 Health technology developers (HTDs) secure spaces created.
- 515 Declarations of interests checked, and individuals onboarded.
- 11 Training sessions given so far.

Constant updates based on users' feedback (next version 4.3.0)



Any other suggestion?

- Up-to-date information https://health.ec.europa.eu/health-technology-assessment_en
 - Ongoing JCAs
 - Implementation rolling plan
 - HTACG Annual Work Programme
 - Key documents legal acts, guidance, agendas, minutes
 - Frequently asked questions
- Announcement and recording of events
 - HTA Conference 2 July <u>EU health technology assessment: Advent of a new era of</u> collaboration - Public Health
 - Webinars (latest 17 October 2025 <u>The EU HTA Regulation: Webinar for health technology</u> developers of medicinal products - Public Health)
- Dedicated pages for experts and HTDs (in preparation)





Evaluation of the HTA Regulation

Article 31(1) of the HTA Regulation

No later than 13 January 2028, the Commission shall present a report to the European Parliament and to the Council on the application of the HTA Regulation incl. on:

- (a) added value for Member States (MSs) of the joint work [...] in particular, whether the health technologies subject to JCAs and the quality of JCAs meet the needs of MSs
- (b) non-duplication of the request of information, data, analyses and other evidence for JCAs for MSs and health technology developers
- (c) functioning of the support framework [...] and, potential need to introduce a fee-paying mechanism





Steps to the evaluation

- Preparation work to start early 2026
- Establishment of an Evaluation Working Group within the HTA Stakeholder Network
- Co-creation of the HTAR evaluation framework
- Close work with the Heads of HTA Agency Group on national reporting



Looking ahead and next steps



- Communication and raise awareness
- Optimise interaction with HTDs
- Learnings from the first JCAs and JSCs, together with experts and stakeholders
- Start planning for the evaluation of the HTA Regulation
 - Member States report by Jan 2027
 - Commission report by Jan 2028
- Positioning of HTA in EU health priorities

Thank you for your attention

Any comments/questions?

To reach the SANTE HTA team, please write to:

SANTE-HTA@ec.europa.eu

